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Abstract: Over a 30-year period, 29 cases of antimalarial retinal toxicity were studied in a 
tertiary medical center. Three cases of chloroquine and 26 cases of hydroxychloroquine toxic-
ity were studied. A number of these cases were studied before multifocal electroretinogram 
(mfERG) became available and show how insensitive the corneal full-field flash ERG is in 
diagnosing this condition. It became apparent that even mfERG failed to diagnose some early 
patients who either had an abnormal fundus examination or Humphrey’s automated perimetry 
(protocol 10-2). The age of the patient and the number of years of exposure to antimalarial 
drugs appears to be directly related to the development of this retinal disorder. All three of the 
“quantitative retinal tests” recommended in the “Guidelines” – mfERG, spectral domain optical 
coherence   tomography (SD-OCT), and autofluorescence – fail to identify all of the cases of 
antimalarial retinal toxicity. mfERG is probably the most sensitive of the three tests, but no direct 
comparison has yet been accomplished. None of these “quantitative tests” appear to provide the 
“gold standard” necessary for detecting early hydroxychloroquine retinal toxicity.
Keywords: chloroquine, hydroxychloroquine, multifocal electroretinogram (mfERG), spectral 
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Introduction
In 2011, the American Academy of Ophthalmology provided revised recommendations 
for the testing of patients taking antimalarial drugs.1 The goal of these guidelines is to 
identify antimalarial retinal toxicity in its earliest stages so that the offending drugs can 
be stopped as early as possible, when clinically indicated. Recommended screening 
procedures include: “a baseline dilated fundiscopic examination (with and with/out 
  fundiscopic photography) and a Humphrey’s automated perimetry (protocol 10-2). 
After 5 years of treatment these tests should be accomplished yearly”. When these 
screening tests become abnormal, consultation with the referring rheumatologist con-
cerning the possibility of stopping the medication should be carried out.   Quantitative 
studies should then be carried out. These include multifocal electroretinogram 
(mfERG), spectral domain optical coherence tomography (SD-OCT), and fundus auto-
fluorescence. When available, mfERG appears to be the most sensitive test followed 
by autofluorescence. Clinicians should be aware that each test has a certain percent-
age of false negatives. In the case of a normal examination and a high suspicion for 
antimalarial toxicity, a second quantitative test should be accomplished.
The purpose of this manuscript is to show that each objective test as carried out at 
this time may show false negative results and that a dilated fundiscopic examination, 
Humphrey’s automated perimetry, and clinical judgement should decide when to stop 
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using the offending agent. Objective tests should be used 
for confirmation of patients with abnormal screening tests. 
In future guidelines, an additional criteria should be added: 
that an individual to receive yearly screenings should be over 
the age of 40 years and have at least 5 years of exposure to 
standard doses of hydroxychloroquine.
Methods
This study represents the experience of a tertiary care cen-
ter providing visual neurophysiologic testing of patients 
from four states: Washington, Alaska, Montana, and Idaho. 
Patients suffering from chloroquine and hydroxychloroquine 
retinal toxicity were referred for study. All of the studies 
were carried out between 1981 and 2011, giving a 30-year 
experience. This is a retrospective study of these patients. 
The patient population included three cases of chloroquine 
and 26 cases of hydroxychloroquine retinal toxicity. All 
patients were female, 26 of the cases were over 40 years of 
age and suffered from a variety of collagen vascular disorders, 
including: four cases of SLE – systemic lupus erythematosus; 
ten cases of rheumatoid arthritis; four cases of Sjögren’s 
syndrome; one case of chronic discoid lupus; one case of 
dermatomyositis; and nine cases of undifferentiated collagen 
vascular disease. Mean age at the time of study: chloroquine 
retinopathy, 64.7 years (range 40–67 years); hydroxychlo-
roquine retinopathy, 63.7 years (range 38–68 years). The 
duration of treatment: patients on chloroquine, 13.3 years 
(range 10–16 years); patients on hydroxychloroquine, 8.0 
years (range 3–20 years). Twenty-four patients complained 
of decreased vision, two had no visual complaints, and three 
complained of blurred vision. All patients received the fol-
lowing doses of the antimalarial medication (approximately 
80% of this population received 400 mg/day hydroyxchlo-
roquine in divided doses, the remaining 20% were either on 
lower doses of 200 mg/day, alternate doses 200 mg/day with 
400 mg/day, or finally one individual who was on a higher 
dose at 600 mg/day). No patient weights were recorded so 
the dose/kg could not be calculated.
Until mfERG became clinically available, patients were 
studied with corneal full-field flash ERGs. Two of the three 
patients with chloroquine retinopathy were studied with 
corneal full-field flash ERG, the third case with mfERG. 
Eighteen patients with hydroxychloroquine toxicity were 
examined by mfERG. Serial studies were accomplished in 
two patients. One of the patients with chloroquine and one 
with hydroxychloroquine were also studied with electro-
  oculograms, only the patient with chloroquine was abnormal, 
the other had a perfectly normal response. Decreased vision 
was the most common complaint. Fundiscopic retinal changes 
were seen in 20 cases, including one case of drusen. Seven 
cases were reported to have no retinal changes. Visual field 
examination was reported in ten cases and corneal deposition 
of hydroxychloroquine was described in two patients.
Corneal full-field flash ERGs, and electro-oculograms, were 
accomplished by methods previously reported.2 The mfERGs 
were accomplished using Sutter Electronic Data Interchange 
(EDI) equipment (Sutter Health, Sacramento, CA) and Veris 
Corporation software. The software provides three levels of 
analysis, 103 kernals, ring summation, and a three-  dimensional 
plot of the data. Luminescence was set at 197 cd/m2 for white 
hexagons and 1 cd/m2 for the black   hexagons. First-order 
kernals were utilized for interpretation.
Results
Dilated fundiscopic examination showed abnormalities 
in all the cases where this information was available. The 
most common retinal change included a Bull’s eye or Target 
maculopathy in both chloroquine and hydroxychloroquine 
retinal toxicity. Fundiscopic photos of the changes seen in 
chloroquine and hydroxychloroquine retinopathy are shown 
in Figure 1A and C.
The earliest of the current studies used the corneal full-
field flash ERG as the quantitative diagnostic test, as the 
multifocal ERG and other quantitative tests had not yet been 
developed. In all, there were nine individuals who under-
went testing with corneal full-field ERG. There were two 
Figure 1 (A) Fundiscopic photo of the retina showing a target maculopathy in 
a patient with chloroquine retinopathy. (B) Fluorescein angiography of same case 
showing a fairly large area of dye leakage extending from the perimacular region. 
(C) Fundiscopic photo of the target maculopathy in a patient with hydroxychloroquine 
retinal toxicity. (D) Fluorescein angiography of this case shows a milder change than 
seen with chloroquine.
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  individuals with chloroquine exposure that showed markedly 
abnormal ERGs, one with both rods and cones being about 
equally affected and the second with cones being affected 
greater than rods. The first case showed a near complete loss 
of all retinal function (end stage retinopathy). Both of these 
individuals had abnormal visual field examinations.
Seven individuals with hydroxychloroquine retinal 
toxicity underwent corneal full-field flash ERGs with three 
being abnormal and four being normal. The three abnormal 
individuals were rated from mildly to moderately abnormal. 
The abnormalities consisted primarily of decreased B-wave 
amplitude with normal implicit times. Cones and rods were 
both affected. One of the individuals with an abnormal cor-
neal full-field flash ERG also had an abnormal visual field 
examination. Two of the four normal individuals with corneal 
full-field flash ERGs had abnormal visual field examina-
tions. All of these nine individuals had abnormal fundiscopic 
examinations with macular pigmentary change, with Bull’s 
eye and Target maculopathy being the most common find-
ings described. With the advent of mfERG, the percentage 
of abnormal cases increased from about 42% using corneal 
full-field ERGs to approximately 72% using mfERGs. In 
summary, corneal full-field flash ERGs are limited in abil-
ity to identify early macular changes and require that the 
disorder is so severe that widespread retinal dysfunction is 
invariably present.
Eighteen individuals, one was exposed to chloroquine and 
seventeen to hydroxychloroquine, underwent mfERG testing 
which is much more specific for examining the   central 40° of 
the retina, 20° on each side of the fixation point. One of the 
potential problems with mfERGs is that Verius Corporation, 
which produces the hardware and software, provides built-in 
normative data. The normative data does not appear to take 
into account changes in the test that occurs with advancing 
age. In our laboratory, a very small sample of asymptomatic 
“normal” adults at 20, 40, and 60 years of age were studied, 
and the mfERG demonstrated a definite change in amplitude 
and implicit time with age. Between 20 and 40 years there 
is an amplitude drop of about 50%, between 40 and 60 years 
the response slows somewhat, but has an amplitude less than 
at 40 years of age (Figure 2). From 20 to 60 years of age the 
implicit time increases from 25 to 29 milliseconds. Since 
the vast majority of patients suffering from antimalarial 
toxicity are older, age-related normative data should be 
generated for future diagnostic use. In order to maximize 
the value of mfERG, future normative studies of at least ten 
individuals per decade from 20 to at least 70 years should 
be carried out.
One patient who had been exposed to chloroquine showed 
severe widespread mfERG changes (Figure 3B). Seventeen 
individuals with hydroxychloroquine toxicity were studied 
with mfERGs. Twelve cases showed the typical loss of   central 
macular dysfunction (Figure 3C). Five cases were found to 
be normal. Of these five cases, two had reduced amplitudes 
thought to be related to age. In those cases that had visual field 
testing and fundiscopic examination, 100% were abnormal. 
mfERG was abnormal in 72% of the hydroxychloroquine 
exposed individuals. Serial studies were carried out in two 
patients with hydroxychloroquine toxicity. In the first case, 
a series of studies was carried out over a 3-year period. 
No worsening of the mfERG or clinical condition over this 
period was documented. The second case underwent serial 
studies over a 10-month period and progression was docu-
mented (Figure 4) along with worsening of the visual field 
examination (Humphrey’s 10-2 protocol) in spite of having 
stopped the offending drug. In two cases, found normal by 
mfERG, the fundiscopic examination showed macular pig-
mentary changes. In one of the two cases found normal by 
mfERG, the perimetric examination was also abnormal. One 
additional patient who was reported to have a normal mfERG 
had a normal fundiscopic examination and an abnormal peri-
metric examination, so that two mfERG normal individuals 
had evidence of the retinal disorder.
Discussion
The incidence and prevalence of antimalarial retinal toxicity 
is unknown. No population studies have ever been reported. 
In our tertiary diagnostic laboratory, during the same time 
period that 29 individuals with antimalarial toxicity were 
referred, there were 267 cases of retinitis pigmentosa. This 
means that retinitis pigmentosa is approximately ten times 
more common than antimalarial retinal toxicity. The inci-
dence of retinitis pigmentosa is reported to be 0.25:1,000 
individuals. One can calculate a relative prevalance for 
antimalarial retinal toxicity at about 0.025:100,000.3–5 Based 
on the variable incidence and prevalence data for the collagen 
vascular disorders in the literature, it is difficult to calculate 
the exact risk to patients with rheumatoid arthritis and SLE 
treated with antimalarials, but from our data it appears that 
less than 1% of the patients treated with antimalarials are 
at risk to develop retinal toxicity. The National Arthritis 
Data Workgroup provide approximate prevalence data for 
rheumatoid arthritis in women at 1.06% of the population 
and SLE to be from 0.05% to 0.1% of the population. The 
percentage of women with rheumatoid arthritis at risk for 
hydroxychloroquine retinal toxicity is about 0.8% while for 
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those women with SLE, the percentage is lower and ranges 
from 0.04% to 0.08%. Our current data on the frequency of 
hydroxychloroquine retinal toxicity agrees well with that 
reported by Tzekow.6
The vast majority of patients with rheumatoid arthritis 
develop symptoms after 40 years of age or older,7,8 while 
patients with SLE generally are symptomatic earlier in life, 
the greatest number being during their reproductive age.9,10 
The age of onset for Sjögren’s disease is generally 45–55 
years of age.11 The differences in the percentage of patients 
developing antimalarial retinal toxicity most likely relate to 
the different ages of onset; rheumatoid arthritis and Sjögren’s 
disease patients generally being older. The mean age for the 
patients with SLE was 50.3 years and each had many years 
of exposure (.15 years) to hydroxychloroquine 400 mg/day 
in divided doses. The mean age for patients with rheumatoid 
arthritis was 56.4 years and each had a shorter length of 
exposure to antimalarial drugs than the SLE cases, two of 
the five individuals having been exposed from 4 and 8 years 
respectively. The mean age for Sjögren’s disease was inter-
mediate between the other two disorders, at 54 years.
Since the purpose of documenting that an individual 
has antimalarial retinopathy, diagnostic tests must identify 
affected individuals as early as possible in order to be able to 
stop these medications before significant retinal changes have 
occurred. It is clear that the corneal full-field flash ERG has 
no place for the testing of chloroquine or hydroxychloroquine 
retinal toxicity. It is not sensitive enough to pick up early focal 
maculopathies. In fact, almost all focal maculopathies have 
an either normal or near normal corneal full-field flash ERG. 
This procedure remains an excellent choice for the diagnosis 
of the diffuse retinopathies, such as retinitis pigmentosa. 
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Figure 2 Age-related changes seen in mfERG testing. The upper part shows the quantitative ring analysis while the lower part shows the three-dimensional analysis. 
Approximately 50% of the response is lost between 20 and 40 years of age. The response stabilizes between 40 and 60 years of age and little further loss occurs. The implicit 
time increases from 25 to 29 milliseconds over the 40 years.
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The   individuals suffering from chloroquine exposure have 
much more severe retinal changes than seen in the typical cases 
of hydroxychloroquine toxicity. Chloroquine tends not only to 
affect the macular region of the retina, but causes widespread 
dysfunction of the entire retina. Its clinical use has stopped for 
the most part and hydroxychloroquine has replaced it for the 
treatment of collagen vascular disorders and as an antimalarial 
agent in Africa and other parts of the world.
Multifocal ERGs are much more sensitive in diagnos-
ing antimalarial retinal toxicity than corneal full-field flash 
ERGs.12–15 This test specifically examines the macular and 
perimacular regions of the retina (central 40°). However, in 
this study mfERG failed to identify at least four individuals 
with hydroxychloroquine toxicity. This means that approxi-
mately 28% of individuals with hydroxychloroquine retinal 
toxicity would be false negatives. That is a high percentage 
0 80 ms
200 nV
0 80 ms
200 nV
0 80 ms
200 nV
Normal A
Chloroquine B Hydroxychloroquine C
Figure 3 (A) Normal responses of the 103 kernals provided by the Veris Corp (The Veris Corporation, McLean, VA) as part of the mfERG package. (B) Widespread loss 
to all responses in the 40° field of testing in a patient with relatively advanced chloroquine retinal toxicity. (C) Focal reduction in the central macular region with normal 
responses at the periphery in a patient with typical hydroxychloroquine retinal toxicity.
20 20 0 deg 0 deg
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Figure 4 Results of a serial study taken over 10 months after patient stopped taking hydroxychloroquine. The panel on the right shows a dramatic reduction in the central 
responses that occurred despite stopping the medication.
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for any type of diagnostic test. This finding raises the ques-
tion of how sensitive mfERG test is in diagnosing very early 
antimalarial retinal toxicity. In this current study perimetry, 
whether it be Goldman’s or Humphrey’s automated peri-
metry, identified nearly 100% of the cases and should remain 
the “gold standard” until more data have been collected 
for mfERG and the other two new diagnostic techniques, 
  SD-OCT15 and fundus autofluorescence.16
In one study,15 24 women with significant hydroxychlo-
roquine exposure were studied. Only six of the 24 had visual 
complaints of decreased visual acuity. All 24 underwent fun-
discopic examination, Humphrey’s automated peri  metry and 
spectral domain optical tomography. Fundiscopic examination 
revealed eleven pigmentary abnormalities, one with drusen, 
and 12 with normal fundiscopic   examinations.   HVF-10-2 
protocol found 13 cases to be abnormal, and eleven normal 
cases. The most common abnormality included scotomata 
of various severities. Five abnormalities were identified with 
SD-OCT. In three of the abnormal cases, a Target maculopa-
thy was identified, one case had retinal pigment epithelial 
changes on fundiscopic examination, but had a scotoma 
on perimetric examination. A single case with a reported 
normal fundiscopic examination had a paracentral scotoma, 
OU. At least two false negatives were reported. One case had 
clinical complaints, central scomata OS . OD by perim-
etry, a normal fundus examination and a negative SD-OCT 
examination. The second case had a complaint of decreased 
visual acuity, a paracentral scotoma, OS . OD by perimetry, 
mild macular puckering on fundiscopic examination and a 
negative SD-OCT. In this study, four individuals showed 
scotomata by perimetry in which the SD-OCT was normal. 
False negatives appear to be even higher for SD-OCT than 
for mfERG testing.
Fundus autofluorescence was compared with mfERG 
in the early detection of  retinopathy in chloroquine and 
hydroxychloroquine retinal toxicity.16 In this study there were 
ten individuals who had a normal Fundus Autofluorescence 
(FAF) and mfERG, five individuals who had a normal FAF 
and abnormal mfERG, two individuals who had an abnormal 
FAF and normal mfERG, and eight individuals where both 
the FAF and mfERG were abnormal. Fundus autofluorescence 
changes included “pericentral ring of increased FAF” and 
“mottled pericentral loss of FAF with adjacent increased in 
FAF”. mfERG abnormalities included decreased amplitude 
of the central kernals with peripheral responses being normal. 
It is clear that FAF studies do not identify all of the cases of 
early antimalarial retinal toxicity, but may pick up a small 
number of individuals not identified by mfERG.
None of the three major tests as currently accomplished, 
mfERG, SD-OCT, and fundus autofluorescence provide 
the sensitivity necessary to meet the objective criteria for 
the recently proposed guidelines1 of early identification of 
individuals suffering from antimalarial retinal toxicity. The 
non-objective tests, Humphrey’s 10-2 protocol automated 
perimetry and fundiscopic examination and photography 
continue to provide the highest yields of early cases and drug 
stoppage when indicated should be based on these studies. 
Objective testing should then be used to confirm the presence 
of antimalarial retinal toxicity knowing that a few affected 
individuals will show normal results. mfERG appears to be 
the most sensitive of the three objective tests, but in the face of 
a normal test when there is a high suspicion from the dilated 
fundiscopic examination and perimetry, a second test should 
be performed and fundus autofluorescence is probably the 
best choice in this situation. Serial studies may also be help-
ful in these cases as progression of retinopathy may occur in 
some of the affected patients after the offending medication 
has been stopped.
At some point, a head-to-head comparison of the three 
quantitative tests should be carried out.
The pathophysiology of antimalarial retinal toxicity 
includes dysfunction of the lysosomes at the retina–retinal 
pigment epithelium (RPE) interface.17 However, that would 
not explain the age population in which this condition devel-
ops. Virtually all cases are older than 40 years and have had 
exposure of greater than 5 years. In this mfERG study, there is 
a dramatic drop in retinal neurons between the ages of 20 and 
40 years of age. It is likely that this loss of nerve cell reserve 
sets the stage for the clinical development of antimalarial 
retinal toxicity. The failure for toxic retinopathy to occur in 
younger individuals is most likely related to the fact that those 
individuals have a significant neuronal reserve which prevents 
the development of clinical disease for many years.
Currently, mfERG, SD-OCT and autofluorescence studies 
should be utilized to objectively diagnose antimalarial retinal 
toxicity, knowing that a certain percentage of early cases will 
be missed, even when more than one test is   utilized. Serial 
studies remain a valuable tool in following the progression 
of the disease. One additional factor which may predispose 
to this condition is the observation by mfERG that there is a 
large loss of responding neurons between 20 and 40 years of 
age. It is this loss of neurons that may predispose the older 
individuals to develop this disorder.
One addition to the recommended guidelines should be 
that individuals be over the age of 40 years in addition to 
having 5 years of exposure before yearly screening begins.
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